Spots Global Cancer Trial Database for Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Official Title: Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy

Study ID: NCT02487069

Conditions

Acute Leukemia

Chronic Myeloid Leukemia

Myelodysplastic Syndrome

Interventions

Antithymocyte globulin

Mycophenolate mofetil

Study Description

Brief Summary: The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.

Detailed Description: Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for a majority of malignant hematologic diseases, especially acute leukemia. HSCT from MSD offers the best results for these diseases, but lack of this donor resource has restricted its wide application. HSCT from MUD provides another option, but MUDs still cannot satisfy all patients due to unsuccessful donor searches. Almost all patients have an available related donor with whom they share a single HLA haplotype (ie, haploidentical related donor), and it owns the advantage of immediate availability, especially for those who urgently need transplantation.The results of transplantation from HRD have improved significantly over the past few years. However, the results from such haploidentical transplantation have not formally been compared with those of transplantation in patients contemporaneously using MSDs and MUDs for hematologic malignancy.